Jumpstart Fertility

Jumpstart Fertility aims to improve the success rate and in turn reduce the reduce the number of treatment cycles, costs, and complications of in vito fertilization (IVF) from aged or chemotherapy-treated mothers using NAD+ precursors. The therapies they develop to this end may also benefit women who have experienced premature infertility and have other benefits.

Jumpstart Fertility is a daughter company of Life Biosciences, which owns multiple rejuvenation biotechnology companies each focusing on a different hallmark of aging. The company is headed by Dr. Lindsay Wu, formerly of Dr. David Sinclair‘s Australian lab, and Dr. Hayden Homer, and with headquarters in Boston, Massachusetts and Sydney, Australia.

Scientists at Jumpstart believe they have uncovered key reasons why female reproduction declines with age and how to correct it, as well as why the separation of chromosomes in egg cells can go awry leading to spontaneous miscarriage or the increased incidence of children born with Down syndrome.

Jumpstart-affiliated researchers published a study in February 2020 entitled “NAD+ Repletion Rescues Female Fertility during Reproductive Aging“. In an experimental model, they showed that “pharmacological or transgenic strategies to replenish the NAD⁺ metabolome ameliorates chemotherapy induced female infertility in mice.” In another study,  “advanced maternal-age [human ovarian tissue] demonstrated related changes in polar metabolites suggested a decrease in mitochondrial function, as demonstrated by NAD+, purine, and pyrimidine depletion, while glycolysis substrates and glutamine accumulated.”

In June 2025, Jumpstart received a $4M investment led by Proto Axiom, along with VU Venture Partners.